HBI Deals+Insights / News
A wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA), the sovereign wealth fund of Abu Dhabi, has become the lead investor in a $230 million single-asset continuation vehicle (CV) established by Chinese healthcare-focused private equity firm GL Capital for SciClone Pharmaceuticals, a US-based biopharmaceutical company.





